Actinic Keratosis News and Research RSS Feed - Actinic Keratosis News and Research

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]
BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions. [More]

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex, Inc. announced today the termination of the exclusive distribution agreement between its wholly-owned subsidiary Radiancy, Inc. and Ya-Man Ltd. for the Japanese market due to, among other things, disputed marketing expenses of approximately $1 million and the failure of Ya-Man to meet its minimum purchase obligations under the agreement. [More]

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013. [More]
Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK. [More]
New study highlights that physicians prefer topical therapies for actinic keratosis

New study highlights that physicians prefer topical therapies for actinic keratosis

Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis’) that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV). [More]
PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com. [More]

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable. [More]

UT professor earns INNOVATOR Award for Cancer Prevention Research at AACR meeting 2013

A proposal to examine the cellular journey from normal skin, to precancerous lesion to skin cancer earned Kenneth Tsai, M.D., Ph.D., the Sixth Annual Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research at the AACR Annual Meeting 2013 in Washington, D.C., April 6-10. [More]

EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

Meda announced today that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis. [More]
Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy. [More]

German BfArM grants Moberg Derma approval to initiate Limtop phase II actinic keratosis trial

The German Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase II trial for Limtop. The aim is to evaluate the efficacy and safety of three different dose regimens of Limtop in a study involving 96 patients with Actinic Keratosis (AK) on the head or face. [More]

New topical gel decreases amount of time needed to treat actinic keratosis

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine. [More]

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma. [More]

PhotoMedex fourth quarter revenues increase 26% to $28.8M

PhotoMedex, Inc. today reported financial results for the three and 12 months ended December 31, 2011. [More]

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis. [More]

Scientists decode unknown mechanism of imiquimod in tumour defense

A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer. [More]

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Moberg Derma AB has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. [More]

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Non-melanoma skin cancer is the most common form of malignancy in adult Caucasian populations, with more than a million cases recorded each year in the USA alone. [More]

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway Pharmaceuticals, LLC announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses. [More]